

RESEARCH ARTICLE

Open Access

Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma

Suat Keskin^{1*}, Zeynep Keskin², Hakan Hakki Taskapu³, Havva Kalkan¹, Mehmet Kaynar⁴, Necdet Poyraz¹ and Hatice Toy⁵

Abstract

Background: To determine the relationship between renal cell carcinoma subtypes and the associated mortality and biochemical parameters. An additional aim was to analyze multiphasic multidetector computed tomography findings.

Methods: This study is a hospital-based retrospective investigation, using 211 patients with a diagnosis of renal cell carcinoma upon computed tomography examination. The histological subtypes included clear cell in 119 patients, chromophobe cell in 30 patients, papillary cell in 25 patients, mixed cell in 32 patients, and sarcomatoid cell in 4 patients.

Results: The mean age of the patients participating in this study was 61.18 ± 11.81 years, and the mortality rate was 10.4% ($n = 22$) through the 2-year follow-up. The ratios of both the neutrophil-to-lymphocyte upon admission to the hospital and platelet-to-lymphocyte of the non-surviving group were significantly higher than those of the surviving group ($p < 0.05$). When the analysis of the 2-year survival of the patients was examined according to the median platelet-to-lymphocyte ratio values, the Kaplan-Meier survival curves were significantly different between the surviving and non-surviving groups ($p = 0.01$). In two-way analysis of variance test, statistically significant results which were influenced by mortality ($p = 0.028$) and were found between renal cell carcinoma subtypes in the computed tomography density of corticomedullary phase ($p = 0.001$).

Conclusions: The neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio may represent widely available biomarkers in renal cell carcinoma, and the logistic regression model indicated that neutrophil-to-lymphocyte ratio was a significant predictor for mortality. According to the median platelet-to-lymphocyte ratio values, the Kaplan-Meier survival curves were significantly different between the surviving and non-surviving groups.

Keywords: Renal cell carcinoma, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, Multiphasic multidetector tomography, Mortality

* Correspondence: drsuatkeskin@yahoo.com

¹Department of Radiology, Necmettin Erbakan University, Meram School of Medicine, Beyşehir Street, Akyokuş, Meram, Konya 42080, Turkey
Full list of author information is available at the end of the article

Background

Renal cell carcinoma (RCC) is the most common primary renal tumor, and originates from the renal cortex [1]. Worldwide, the incidence of RCC has increased over the last thirty years [2]. After the surgical treatment of RCC, the possibility of recurrent tumors is 10-20% [3-5] therefore, with the recent peripheral blood sampling in the diagnosis of RCC, the development of different prognostic factors is necessary. For this purpose, some prognostic markers and models have been developed; [6,7] for example, changes like neutrophilia, lymphopenia, and thrombocytosis in the peripheral blood are evaluated in response to systemic inflammation. Prognostic factors, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), are used for an assessment of the response to systemic inflammation and RCC prognosis [8-11]. Various studies have shown that a high NLR is associated with poor prognosis in RCC; however, in most of these studies, clear cell, non-clear cell, metastatic, and non-metastatic RCC groups were included [11-14]. The relationship of the histological RCC subtypes with the prognostic factors, such as NLR, PLR, or mortality, has not been actively discussed in the literature. In this study, clear cell/non-clear cell or metastatic/non-metastatic differentiation has been made. Also, multiphasic multidetector computed tomography (CT) findings are included, in addition to the hematological parameters. Most commonly used imaging modality in the detection of renal masses is multidetector CT. Many studies in the past reported significant findings that revealed the different enhancement patterns of RCC subtypes on multidetector CT [15-17].

Methods

Study population

This study is a hospital-based retrospective investigation, where 231 patients with RCCs over the age of 18, who were admitted to the Meram Medical School Hospital, were screened between January of 2008 and March of 2013, were enrolled in the study after providing written informed consent. Patients with a diagnosis of RCC upon computed tomography (CT) examination were included in the study. The RCCs were diagnosed by resection, and 20 patients without pathological correlation were excluded from the study population. This retrospective study was approved by the Necmettin Erbakan University, Meram School of Medicine Hospital Institutional Review Board.

Study protocol

The RCC cases were screened from the database of the hospital's electronic record system. The demographic and clinical characteristics of 211 patients who met the inclusion criteria were obtained from the patient's archived records to evaluate mortality. RCCs were detected via

multiphasic multidetector CT, and hospital mortalities of the patients were determined according to their medical records. Fuhrman grade system was used for pathological grading in RCC.

Blood sample analysis

A complete blood count analysis was performed using the peripheral venous blood samples taken upon admission to the urology department of the hospital. The blood samples were collected in a calcium EDTA (Ethylenediaminetetraacetic acid) tube, and blood counts have been evaluated using an auto-analyzer (Abbott Cell-Dyn Ruby Hematology Analyzer, Illinois, USA) in our hospital since 2007. The NLR was calculated as the ratio of neutrophils to lymphocytes, and the PLR was calculated as the ratio of platelets to lymphocytes in the peripheral blood. In addition, other routine laboratory findings were examined using the digital record systems of the hospital.

Equipment and scanning

One radiologist (SK), with 9 years of experience in CT, carried out the multiphasic multidetector CT examinations. All of the patients were examined using a 64-multidetector CT (64-MDCT) scanner (Siemens SOMATOM Sensation 64, Erlangen, Germany) with the following scanning parameters: 0.6 mm collimation, 1.5 mm slice thickness, 1.4 mm increment, 100 kV and 135 mAs, a pitch of 0.9, and a gantry rotation time of 0.33 s. A scout image was acquired while the patient was in the supine position, and the area from the diaphragm to the end of the iliac bones was identified as the field of examination. All patients received 100 ml of nonionic contrast medium (Ultravist 300; Bayer Schering Pharma, Berlin, Germany), which was managed through a catheter in the right antecubital vein. The contrast was executed at a flow rate of 5 mm/sec using an automated injector, and the scan was executed 20 s after the start of the injection. Firstly, unenhanced phase was obtained. After the nonionic contrast medium was given, the corticomedullary phase in the 25th second, nephrographic phase in the 60th second, and excretory phase in the 5th minute were obtained. Lesion sizes were measured in the nephrographic phase and densities were measured in the unenhanced, corticomedullary, nephrographic and excretory phases. Density measurements were made from the 3 separate 10 mm² solid circular region of interest (ROI) field in the mass and then the average of these values were calculated for the mass attenuation. The most homogeneous and dense contrast enhanced areas were used to obtain the attenuation values. In contrast, we avoided from necrotic, cystic and calcified areas to measure the density.

Statistical analysis

Statistical analyses were performed using SPSS version 20.0 software (SPSS, Chicago, IL, USA), and the data

were presented as the mean \pm standard deviation or median (interquartile range [IQR]). Subsequently, the lesion sizes were categorized as less than 40 mm, 41–80 mm, 81–120 mm, 121–160 mm, and 161–200 mm. Distribution normality was analyzed with the Kolmogorov-Smirnov test, and the differences between the two groups were tested using the independent Student's *t*-test for normally distributed variables, while the Mann–Whitney U test was used for a comparison of the non-parametrically distributed variables. The differences between the categorical variables were determined by using the χ^2 -test. While investigating the associations between non-normally distributed and/or ordinal variables, the correlation coefficients and their significance were calculated using the Spearman test. One-way analysis of variance was used to compare CT density among the subtypes of RCCs. Levene's test was used to assess the homogeneity of the variances. When an overall significance was observed, pair wise post-hoc tests were performed using Tamhane's T2 test. When investigating the changes in lesion density of corticomedullary phase by RCC's subtypes, the effects of mortality was adjusted using two-way analysis of variance test respectively. Kruskal-Wallis tests were conducted to compare the differences in CT density and NLR among the pathological subtypes, and hemoglobin and creatinine among lesion sizes and tumor stage. The Mann–Whitney U test was performed to test the significance of the pair-wise differences using the Bonferroni correction to adjust for multiple comparisons. Two-tailed *P* values of less than 0.05 were accepted to be statistically significant. The logistic regression analysis was performed to determine the predictors of 2-year mortality. The hematological parameters, age, gender, NLR, and PLR were included in this regression model as independent variables. The best cut-off value of the hematological parameters was estimated using regression tree analysis.

Results

The mean age of the 211 patients who were diagnosed with renal cell cancer was 61.18 ± 11.81 years, and the mortality rate was 10.4% ($n = 22$) by the 2-year follow-up. The histological subtype was clear cell carcinoma in 119 patients, chromophobe cell carcinoma in 30 patients, papillary cell carcinoma in 25 patients, mixed cell carcinoma in 32 patients, and sarcomatoid cell carcinoma in 4 patients. The mean and 95% CI of CT density were demonstrated in subtypes of RCCs (Table 1). Demographic and laboratory findings of the surviving and non-surviving patients are reported in Table 2. Both the NLR upon admission to the hospital and the PLR of the non-surviving group were significantly higher than those of the surviving group ($p < 0.05$). Also, there were significant differences in age, lesion size, WBCs, neutrophils, lymphocytes, platelets, hemoglobin, creatinine, metastasis, and tumor stage (Table 2).

Age, NLR, hemoglobin, and creatinine were independent predictors of mortality in the logistic regression analysis (Table 3). The optimal cut-off value for NLR as a predictor of mortality was determined to be 2.7 in the ROC curve analysis. On this level, the sensitivity was 81.8%, specificity was 59.3%, positive predictive value was 18.9%, and the negative predictive value was 96.6% (Figure 1). There is no significant difference in NLR between pathological subtypes ($p = 0.928$). The optimal cut-off value for the PLR was determined to be 151. When the analysis of the 2-year survival of the patients was examined according to median PLR values, the Kaplan-Meier survival curves were significantly different between the surviving and non-surviving groups ($p = 0.01$) (Figure 2). In the Mann–Whitney U test, statistically significant results were found in the WBCs ($p = 0.021$), platelets ($p = 0.003$), hemoglobin ($p < 0.001$), lesion density of excretory phase ($p = 0.048$) and creatinine ($p < 0.001$) between the male and female patients; the PLR ($p = 0.04$) and lesion density of corticomedullary phase ($p = 0.001$) between the clear cell and non-clear cell lesions; and the lesion size ($p < 0.001$), creatinine ($p < 0.001$), and hemoglobin ($p = 0.001$) between metastasis and non-metastasis. When the males and females were compared, there was a statistically significant difference in the metastasis between the two groups ($p = 0.02$). In the Kruskal-Wallis test, there was a statistically significant difference in corticomedullary phase's density between the clear cell and papillary ($p < 0.001$), chromophobe and papillary ($p = 0.016$), and papillary and mixed ($p = 0.002$) RCCs. In the Kruskal-Wallis test, there was a statistically significant difference in hemoglobin and creatinine between stage 1 and 4 ($p < 0.001$). In the independent Student's *t*-test, the lesion's density in corticomedullary phase was found 21,12 HU higher than men in women ($p = 0.034$ CI%95 1,59-40,65), the lesion's density in corticomedullary phase was found 27,34 HU higher than non-clear cell RCCs in clear cell RCCs ($p = 0.006$) (CI%95 8,16-46,53), the lesion's density in nephrographic phase was found 19,73 HU higher than non-clear cell RCCs in clear cell RCCs ($p < 0.001$) (CI%95 9,04-30,42) and the lesion's density in corticomedullary phase was found 29,53 HU higher than non-surviving in surviving group ($p = 0.048$) (CI%95 0,23-58,47). In the One-way analysis of variance test, statistically significant results were found between clear cell and papillary ($p < 0.001$), clear cell and sarcomatoid ($p < 0.001$), papillary and mix ($p = 0.046$), papillary and sarcomatoid subtypes ($p < 0.031$) in the lesion density of early arterial phase. Statistically significant results were found between clear cell and papillary ($p = 0.001$), papillary and mix ($p = 0.039$) in the lesion density of nephrographic phase. In Spearman test, positive medium correlation (r 0.40-0.60) was found between unenhanced and corticomedullary phases. Positive good correlation (r 0.60-0.70) was found between unenhanced and corticomedullary phases. Positive good

Table 1 The mean and 95% CI of CT density in subtypes of RCCs

	Clear cell RCC		Chromophobe RCC		Papillary RCC		Mixed RCC		Sarcomatoid RCC	
	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI
unenhanced	31,43 ± 1,50	28,41-34,45	38,25 ± 5,35	25,60-50,90	31,70 ± 3,81	23,08-40,32	33,78 ± 3,42	25,90-41,65	29,50 ± 1,50	10,44-48,56
corticomedullary	118,24 ± 5,83	106,47-130,01	117,38 ± 18,21	74,33-160,42	58,20 ± 5,21	46,41-69,99	106,33 ± 12,49	77,52-135,15	79,00 ± 1,00	66,29-91,71
nephrographic	92,83 ± 2,78	87,23-98,44	88,13 ± 12,54	58,47-117,78	55,10 ± 6,24	40,99-69,21	82,56 ± 5,38	70,15-94,96	60,50 ± 9,50	60,21-181,21
excretory	66,62 ± 2,42	61,74-71,50	63,00 ± 9,45	40,66-85,34	51,70 ± 7,23	35,33-68,07	66,56 ± 5,62	53,61-79,50	47,50 ± 4,50	9,68-104,68

RCC: Renal cell cancer, CI: Confidence interval, CT: Computed tomography.

Table 2 Demographics and laboratory findings of survived and non-survived patients

	Survived (n = 189) mean ± SD/median (IQR)	Non-survived (n = 22) mean ± SD/median (IQR)	P	Z
Age years	58.1 ± 13.5	67.9 ± 12.5	0.005	
Gender (F/M)	69/120	7/15	0.665	
Lesion size	56.9 ± 30.6	75.2 ± 35.2	0.004	-2.853
WBC (10 ³ /uL)	7.89 (7.63)	11.96 (10.30)	0.002	-3.075
Neutrophil (10 ³ /uL)	5.09 (4.92)	8.50 (7.71)	0.002	-3.033
Lymphocyte(10 ³ /uL)	2.13 (2.01)	2.08 (2.10)	0.457	-0.744
NLR	2.60 (2.24)	4.28 (3.75)	<0.001	-3.733
Platelet (10 ³ /uL)	259.0 ± 73.1	306.1 ± 65.9	0.028	-2.203
PLR	134.2 (124.0)	150.2 (145.0)	0.038	-2.079
Hemoglobin mg/dl	13.0 ± 1.8	12.4 ± 1.6	0.001	-3.371
MPV	7.24 (7.20)	7.13 (7.86)	0.430	-0.790
Creatinine mg/dl	0.9 ± 0.3	1.2 ± 0.8	0.046	-1.996
CT density (HU)				
Unenhanced	32.9 ± 1.4	29.7 ± 3.1	0.401	
Corticomedullary	110.8 ± 5.3	81.4 ± 10.1	0.048	
Nephrographic	86.5 ± 3.1	73 ± 5.3	0.118	
Excretory	64.2 ± 2.5	59 ± 4.4	0.522	-0.640
Metastasis	44	12	0.002	9.88 chi-square
Pathologies Clearcell/Nonclear cell	103/86	16/6	0.103	
Chromophobe/ Papillary/Mix/Sarcomatoid	29/25/29/2	1/0/3/2	0.692	
Tumor Stage 1/2/3/4	105/27/13/44	7/1/2/12	0.005	-2.788

IQR: interquartile range, WBC: White blood cell count, NLR: Neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, MPV: Mid-platelet volume, CT: Computed tomography, HU: Hounsfield unit.

correlation (r 0.60-0.70) was found between corticomedullary and nephrographic phases. Positive excellent correlation (r 0.75-1.00) was found between nephrographic and excretory phases (p < 0.05). In two-way analysis of variance test, statistically significant results which were influenced by mortality (p = 0.028) and were found between RCCs subtypes in the CT density of corticomedullary phase (p = 0.001).

Table 3 Logistic regression results for the predictors of mortality

Variables	Odds ratio	95.0% CI HR	P
The first step			
Age	1.05	1.01-1.10	0.015
Gender	0.96	0.35-2.59	0.93
NLR	3.21	1.26-8.16	0.014
PLR	1.79	0.60-5.30	0.29
Hemoglobin	5.33	1.56-18.23	0.008
Creatinine	3.34	1.12-9.99	0.031

NLR: neutrophil/lymphocyte ratio, PLR: platelet/ lymphocyte ratio.

Discussion

The aim of this study was to determine the relationship between RCC subtypes and the associated mortality and biochemical parameters. An additional aim was to analyze the multiphasic multidetector CT findings. Previous studies have revealed that inflammatory markers are associated with RCC prognosis [18]. The NLR is a systemic inflammation marker with a wide range of use, low cost, and easy accessibility [19-21], and previous studies have concluded that the NLR is a predictor of mortality in RCC patients [22,23]. As far as we know, inflammatory markers, such as the NLR and PLR, have been studied in RCC patients after they were classified generally as metastatic or not. However, these studies were focused on clear cell and metastatic RCCs. Additionally, in our study, the relationships between the RCC histological subtypes and mortality, systemic markers, and multiphasic multidetector CT findings were investigated. Our results suggest that in patients with RCC, there is a statistically significant difference in the NLR between survivors and non-survivors.

The logistic regression model indicated that the NLR was a significant predictor for mortality. Similar to our




Figure 1 ROC curve showed predictive value of NLR for death.




Figure 2 Kaplan Meier survive curve according to the PLR median value.

findings, Ohno et al. concluded that high preoperative NLR values are a predictor indicating mortality in RCC [13]. However, unlike us, Jagdev et al. found that a high NLR is not a predictor of prognosis in RCC [24]. Pichler et al. inferred (different from us) that the preoperative NLR is a predictor for mortality only in non-metastatic clear cell RCC [25]. According to the median PLR values, the Kaplan-Meier survival curves were significantly different between the surviving and non-surviving groups. The role of the histological subtype (papillary vs. chromophobe) as an independent prognostic factor in localized RCC, however, is still unclear.

In the literature, there were several studies including patients with clear cell RCC and the subtypes [13,24-26]. However, there were no detected significant differences in mortality between the histological subtypes in our study. Dirican et al. [27] found no association between age, platelet count, neutrophil count, PLR, and mortality in metastatic RCC, except in lung metastasis. We found a significant difference between age, platelet count, neutrophil count, PLR, and mortality in metastatic and non-metastatic RCC.

In addition, we investigated the association between multiphasic multidetector CT findings and the other parameters in RCC. It is noted that mortality increased with an increased size of the lesion. Additionally, a significant difference with reference to CT density was determined in the evaluation of the lesion density between RCCs subtypes in corticomedullary and nephrographic phases. Similarly with Young et al. [28], significant difference between clear cell and papillary subtype in terms of lesion density on corticomedullary and nephrographic phase was detected. However, we didn't identify difference on excretory phase. In our study, lesion density on corticomedullary phase was significantly higher in the dead patients compared with alive patients. Also, it is understood that there is significant difference between the RCC subtypes on corticomedullary phase and mortality effect this. Unlike Young et al. significant difference was detected between clear cell and sarcomatoid; papillary and mixed papillary; papillary and sarcomatoid subtypes. Besides, Young et al. calculated the average of two density values obtained from the two separate areas of the lesion. However we have the average density values of three different homogeneous enhanced areas. Unlike Jung et al. [29], attenuation values obtained on corticomedullary and nephrographic phases for clear cell were significantly higher than the non-clear cell ones. Again, different from Jung et al. our patient population was higher and additionally mixed and sarcomatoid types were included in our study. Also, differently, four phased CT examination was obtained. Jung et al. didn't detect density differences in terms of gender. In our study, there was significant difference detected between

male and female in terms of lesion density on the late phase. Unlike Kim et al. [30] there was statistically significant difference for lesion density on corticomedullary phase between clear cell and papillary; clear cell and sarcomatoid; papillary and mixed; papillary and sarcomatoid subtypes. On nephrographic phase in terms of lesion density, significant difference was detected between clear cell and papillary; papillary and mixed subtypes.

Our study is retrospective so it has some limiting factors. The pathological evaluation was performed by two different pathologists, and some prognostic factors, such as tumor necrosis, was not taken into consideration. Furthermore, the organs which the RCC metastasized to were not classified in and of themselves. In the evaluation of biochemical markers, only the preoperative period was taken into consideration, but the postoperative values were not included in the study. Clear cell RCC occurs more often than the other subtypes, and studies in which the clear cell and other subtypes are distributed homogeneously will provide more optimal results.

Conclusions

As a result of this study, the NLR and PLR were determined to be easily accessible markers in the prognosis of RCC, and the usage of these markers may be helpful in the management of high-risk RCC patients. In addition, multidetector CT is useful to detect the differences in contrast enhancement patterns between the RCC subtypes.

Abbreviations

CT: Computed tomography; EDTA: Ethylenediaminetetraacetic acid; IQR: Interquartile range; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; RCC: Renal cell carcinoma; ROI: Region of interest.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SK and HHT drafted the manuscript. SK also designed the experiments and interpreted the data. ZK and HK made statistical analysis. SK and NP measured the lesion densities. MK and HT contributed to the design and conception. SK revised this manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by Department of Urology in Necmettin Erbakan University Meram School of Medicine.

Author details

¹Department of Radiology, Necmettin Erbakan University, Meram School of Medicine, Beyşehir Street, Akyokuş, Meram, Konya 42080, Turkey. ²Department of Radiology, Konya Training and Research Hospital, Konya, Turkey. ³Department of Urology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. ⁴Department of Urology, Selçuk University, School of Medicine, Konya, Turkey. ⁵Department of Pathology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey.

Received: 6 August 2014 Accepted: 18 November 2014

Published: 26 November 2014

References

1. AJCC: *Cancer Staging Manual*. 7th edition. New York Inc: Springer; 2010.

2. Siegel R, Naishadham D, Jemal A: **Cancer statistics.** *CA Cancer J Clin* 2012, **62**(1):10–29.
3. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: **Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.** *J Clin Oncol* 2002, **20**(23):4559–4566.
4. Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C: **Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.** *BJU Int* 2012, **110**(11):553–558.
5. Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Chevill JC, Lohse CM, Boorjian SA: **Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.** *Urology* 2011, **78**(5):1101–1116.
6. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P: **A postoperative prognostic nomogram for renal cell carcinoma.** *J Urol* 2001, **166**(1):63–67.
7. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: **Improved prognostication of renal cell carcinoma using an integrated staging system.** *J Clin Oncol* 2001, **19**(6):1649–1657.
8. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF: **Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin.** *Am J Respir Crit Care Med* 1999, **159**(3):857–863.
9. Dionigi R, Dominioni L, Benevento A, Giudice G, Cuffari S, Bordone N, Caravati F, Carcano G, Gennari R: **Effects of surgical trauma of laparoscopic vs. open cholecystectomy.** *Hepatogastroenterology* 1994, **41**(5):471–476.
10. O'Mahony JB, Palder SB, Wood JJ, McIrvine A, Rodrick ML, Demling RH, Mannick JA: **Depression of cellular immunity after multiple trauma in the absence of sepsis.** *J Trauma* 1984, **24**(10):869–875.
11. Zahorec R: **Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill.** *Bratisl Lek Listy* 2001, **102**(1):5–14.
12. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P: **Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma.** *Am J Surg* 2009, **197**(4):466–472.
13. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M: **Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma.** *J Urol* 2010, **184**(3):873–878.
14. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M: **Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma.** *J Urol* 2012, **187**(2):411–417.
15. Sheir KZ, El-Azab M, Mosbah A, El-Baz M, Shaaban AA: **Differentiation of renal cell carcinoma subtypes by multislice computerized tomography.** *J Urol* 2005, **174**(2):451–455.
16. Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, Debré B, Amsellem-Ouazana D: **Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification.** *Urology* 2007, **69**(2):230–235.
17. Mydlo JH, Weinstein R, Misseri R, Axiotis C, Thelmo W: **Radiologic, pathologic and molecular attributes of two types of papillary renal adenocarcinomas.** *Scand J Urol Nephrol* 2001, **35**(4):262–269.
18. Sejima T, Iwamoto H, Morizane S, Hinata N, Yao A, Isoyama T, Saito M, Takenaka A: **The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.** *Urol Oncol* 2013, **31**(7):1343–1349.
19. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA: **The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.** *Eur J Cancer* 2012, **48**(2):202–208.
20. Ramsey S: **The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell carcinoma.** *Mol Diagn Ther* 2009, **13**(5):277–281.
21. Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, Barré O, Bruckert F, Dubourg O, Lacombe P: **New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography.** *Am J Roentgenol* 2001, **176**(6):1415–1420.
22. Wu AS, Pezzullo BAJ, Cronan JJ, Hou DD, Mayo-Smith WW: **CT pulmonary angiography: quantification of pulmonary embolus as a predictor of patient outcome—initial experience.** *Radiology* 2004, **230**(3):831–835.
23. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, Capodilupo R: **Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure.** *Am J Cardiol* 2011, **107**(3):433–438.
24. Jagdev SP, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, Cartledge J, Selby PJ, Banks RE: **Improving the accuracy of preoperative survival prediction in renal cell carcinoma with C-reactive protein.** *Br J Cancer* 2010, **103**(11):1649–1656.
25. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R: **Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.** *Br J Cancer* 2013, **108**(4):901–907.
26. Ramsey S, Lamb GW, Aitchison M, McMillan DC: **Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer.** *BJU Int* 2008, **101**(8):959–963.
27. Dirican A, Kucukzeybek Y, Somali I, Erten C, Demir L, Can A, Bahriye Payzin K, Vedat Bayoglu I, Akyol M, Koseoglu M, Alacacioglu A, Oktay Tarhan M: **The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.** *JBUON* 2013, **18**(2):413–419.
28. Young JR, Margolis D, Sauk S, Pantuck AJ, Sayre J, Raman SS: **Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.** *Radiology* 2013, **267**(2):444–453.
29. Jung SC, Cho JY, Kim SH: **Subtype differentiation of small renal cell carcinomas on three-phase MDCT: usefulness of the measurement of degree and heterogeneity of enhancement.** *Acta Radiologica* 2012, **53**(1):112–118.
30. Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KR, Cho KS: **Differentiation of subtypes of renal cell carcinoma on helical CT scans.** *Am J Roentgenol* 2002, **178**(6):1499–1506.

doi:10.1186/1471-2490-14-95

Cite this article as: Keskin et al.: Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma. *BMC Urology* 2014 **14**:95.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

